What Happens When the FDA Places a Clinical Trial on Hold?

A clinical hold is one of the most consequential regulatory actions the FDA can take during the life of an investigational drug program. When a hold is issued, an Investigational New Drug (IND) application cannot move forward as planned. New participants cannot be enrolled in the affected studies, and in most cases, participants already in those studies are taken off the investigational therapy until the cited deficiencies are resolved.

For anyone working in or around clinical trials, understanding what a clinical hold is, what triggers it, and how it is resolved is part of understanding the broader FDA framework that governs clinical research in the United States.

How a Clinical Hold Works

A clinical hold is an order issued by the FDA to the sponsor of an IND application to delay a proposed clinical investigation or suspend one already underway. The hold may apply to every study under an IND or only to specific studies named in the order.

Holds are typically issued by the Division Director of the FDA Review Division responsible for the IND. The order may be communicated by telephone or other rapid means of communication, with a written explanation following within 30 days. The written explanation identifies the studies affected and the deficiencies that triggered the action.

Before imposing a hold, the FDA generally tries to discuss and resolve the matter with the sponsor first. The exception is when participants face immediate and serious risk, in which case the order takes effect right away.

Holds come in two forms. Under a full clinical hold, no study activities under the affected IND may proceed. New participants cannot enroll, and existing participants are generally taken off the investigational therapy unless the FDA specifically permits continuation in the interest of participant safety. The FDA framework for balancing trial integrity and participant burden is discussed in Reducing Participant Burden: Insights from FDA Guidance.

Under a partial clinical hold, the FDA restricts only certain activities. The agency may pause new enrollment while permitting dosing to continue for participants already on study. The agency may restrict dosing at certain levels while allowing lower doses to continue. The specific activities that may continue and those that are paused are set out in the FDA hold order.

What Triggers a Clinical Hold

The grounds for a clinical hold are set out in 21 CFR 312.42 and depend partly on the phase of the affected study.

Across all phases, the FDA may impose a hold when:

• Participants face an unreasonable and significant risk of illness or injury
• Investigators are not qualified by scientific training and experience to conduct the trial
• The investigator brochure is misleading, erroneous, or materially incomplete
• The IND application lacks sufficient information to assess participant risk
• A study of a treatment for a life-threatening condition unjustifiably excludes men or women with reproductive potential

For Phase 2 and Phase 3 trials, the FDA can also impose a hold when the protocol is clearly deficient in design and unlikely to meet its stated objectives. Protocol design as a broader topic is examined in Patient-Centric Protocol Design: A Sponsor's Guide.

According to FDA research, product quality issues are the most common reason trials are placed on hold, followed by clinical and toxicology concerns. Specific examples cited by the FDA include impurity profiles that suggest a potential health hazard, formulations that cannot remain chemically stable across the testing program, animal data insufficient to support the proposed exposure, and previously observed toxicities that the proposed safety assessments do not adequately address.

Gene therapies and other next-generation modalities can raise additional manufacturing questions around impurities, degradation products, and metabolites that have not been qualified in a non-clinical safety model.

While a Hold Is in Place

While a clinical hold is in place, the affected studies cannot move forward as planned. The IND itself remains active, but no new participants can be enrolled in the affected studies, and dosing is paused according to the terms of the hold order. Site activation stalls. Enrollment momentum dissipates. Downstream development decisions wait. The cost of recruitment delays compounds the longer a pause continues, a dynamic explored in The Hidden Cost of Slow Recruitment in Clinical Trials: Why Time-to-First-Patient Matters.

For public companies, a clinical hold is treated as material non-public information under federal securities laws. Decisions about disclosure, trading restrictions, and the impact on ongoing offerings or corporate transactions are coordinated with counsel.

If all investigations under an IND remain on hold for one year or longer, the FDA may consider the IND for Inactive Status. Inactive Status carries additional regulatory implications and signals that more work may be needed before development resumes.

The Path to Lifting a Hold

The formal regulatory route from a hold letter to a lifted hold runs through two steps: a Type A Meeting and a Complete Response.

A Type A Meeting is the FDA meeting type reserved for critical issues, including clinical hold resolution. The FDA typically grants Type A Meetings within 30 days of the request, and the meeting package is submitted alongside the meeting request. During the meeting, the FDA clarifies its expectations and guides the sponsor on how to proceed with the Complete Response.

A Complete Response is the formal written submission that addresses each deficiency identified in the hold letter. Depending on what the FDA flagged, a Complete Response can include additional preclinical data, clinical protocol modifications around patient selection or dosing, Chemistry, Manufacturing, and Controls (CMC) updates covering formulation or stability, new risk mitigation and monitoring plans, or scientific justifications drawing on literature and regulatory precedent.

Once a Complete Response is submitted, the FDA has 30 calendar days to review it. There are three possible outcomes. The hold is lifted and the investigation may resume. The FDA requests further clarification or modifications. Or the hold remains in place if the issues have not been adequately resolved.

A sponsor that disagrees with the basis for the hold may request reconsideration through the FDA Ombudsman, in accordance with Dispute Resolution procedures.

Communications with sites, IRBs, and partners run in parallel with the regulatory submission work. Site investigators, IRBs, ethics committees, and contractually obligated partners are notified of the hold and of the steps being taken to address it. The oversight infrastructure that supports this kind of cross-site coordination is examined in CTMS Essentials for Sponsors: Oversight, Budgets & Compliance.

When a Hold Is Lifted

When the FDA notifies the sponsor that the hold has been lifted, the trial may resume. Before new enrollment can begin, several operational steps typically need to happen at the affected sites: site re-engagement, protocol-amendment implementation, IRB approvals for any protocol changes, and updated participant communications.

For sponsors and sites restarting recruitment after a hold, structured patient intake workflows can support a smoother re-launch. The mechanics of intake workflow design are examined in Streamlining Participant Intake Workflows for Sponsors.

DecenTrialz operates in this layer of the trial ecosystem. The platform uses AI-assisted patient matching and nurse-led pre-screening to feed eligible candidates into site workflows efficiently, supporting sponsor recruitment timelines whether a trial is launching for the first time or restarting after a hold. Enrollment, informed consent, and all medical decisions remain with the research site and study team. Visit decentrialz.com for more on sponsor recruitment partnerships.